Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

Efficacy and Safety Study of MK0359 in Patients with Arthritis

Completed

Looking for future studies?

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

You are 18-65 years of age and have Rheumatoid Arthritis
You must be able to read and understand patient questionnaires

Exclusion criteria

You have had certain types of surgery, certain types of cancer or history of Tuberculosis (TB) or HIV.

Treatment and study plan

MK0359

Drug

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Important dates

Study start: 2002
Primary completion: 2003
Study completion: 2003
First posted: Jun 5, 2007
Registry last updated: Nov 20, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed